Introduction: Epidemiologic data demonstrate a strong inverse correlation between high-density lipoprotein cholesterol (HDL-C) and cardiovascular disease risk. We recently extended this observation to include an association of low HDL-C with incident cancer in a systemic analysis of lipid-altering trials. The role of HDL-C in relation to cancer risk, however, remains unclear. At issue is a potential contribution of underlying processes that simultaneously affect HDL-C concentration and promote carcinogenesis, such as smoking, obesity, or hyperinsulinemia. Alternatively, low HDL-C levels may themselves manifest from active neoplastic processes (reverse causality). We examined these issues using data from the Framingham Heart Study Offspring Cohort to assess trends in HDL-C throughout time preceding cancer diagnosis.
